Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04240106
Title Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN)
Acronym LUZERN
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors MedSIR
Indications
Therapies
Age Groups: adult | senior
Covered Countries ESP


No variant requirements are available.